New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
09:02 EDTINWK, SNYSanofi, InnerWorkings sign global marketing partnership
InnerWorkings (INWK) has been selected as a global marketing partner of Sanofi (SNY). Under this agreement, InnerWorkings will oversee the creation, production, and management of Sanofi’s worldwide promotional items, with a special focus on implementing high standards for corporate and social responsibility across global operations. Additionally, InnerWorkings will drive enhanced innovation, stewardship, and consistency across Sanofi’s global efforts. InnerWorkings and Sanofi began its partnership in 2013 with a pilot program to support Sanofi’s work in 15 countries across the Americas, Europe and Africa. Throughout the rest of 2014, InnerWorkings will expand this solution to dozens more countries and regions.
News For SNY;INWK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
08:34 EDTINWKInnerWorkings sell-off on CFO change overdone, says Barrington
Subscribe for More Information
January 26, 2015
05:14 EDTSNYRegeneron, Sanofi announce BLA for Praluent accepted for priority review by FDA
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the Biologics License Application, or BLA, for Praluent, alirocumab. Under the Prescription Drug User Fee Act, or PDUFA, the goal for a priority review is six months, for a target action date of July 24. Alirocumab is an investigational monoclonal antibody targeting PCSK9 that is intended for the treatment of patients with hypercholesterolemia. The BLA for Praluent contains data from more than 5,000 patients, including 10 Phase 3 ODYSSEY trials. Together with additional ongoing studies including ODYSSEY OUTCOMES, the ODYSSEY clinical trial program will include more than 23,500 patients at more than 2,000 study centers in double-blind, randomized, placebo-and active-controlled trials ranging from 24 weeks to approximately 5 years. Earlier this month, the companies announced that the European Medicines Agency accepted for review the Marketing Authorization Application for Praluent in the European Union. The EMA and FDA have conditionally accepted Praluent as the trade name for alirocumab. The safety and efficacy of alirocumab have not been fully evaluated by any regulatory authority.
January 22, 2015
18:13 EDTINWKInnerWorkings, Edrington sign multi-year agreement
InnerWorkings was named U.S. marketing partner of Edrington, the international maker of iconic Scotch whiskies and other premium spirits. Under the long-term multi-year agreement, InnerWorkings will produce Edrington’s print, point-of-sale, and other branded materials throughout the U.S. This agreement expands InnerWorkings’ relationship with Edrington into the U.S. Since 2012 InnerWorkings has developed and distributed luxury packaging for Edrington’s brands – The Macallan, Brugal, Cutty Sark, Snow Leopard, and others – in other regions around the globe. Ranked as a top global partner by Edrington in 2014, InnerWorkings also was recently selected as Edrington’s exclusive Russian provider of packaging, point-of-sale displays, and printed marketing and promotional materials.
05:22 EDTSNYGenzyme Cerdelga granted marketing authorization by EC
Subscribe for More Information
January 21, 2015
10:16 EDTSNYLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
January 20, 2015
09:18 EDTINWKInnerWorkings reports CFO Busky leaving company
InnerWorkings announced the appointment of Ryan Spohn as interim Chief Financial Officer. Spohn will succeed Joseph Busky, who is leaving the company to pursue other business opportunities. Busky will remain as CFO through the filing of the company’s Annual Report on Form 10-K for the year ended December 31, 2014, at which time Spohn’s appointment will take effect. Spohn will oversee the company’s financial operations on an interim basis, while the company conducts a formal search for a replacement. Busky will continue to serve in an advisory capacity ending by June 30, 2015 to ensure a smooth transition, the company said.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use